Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Lifecare's latest analyst update keeps the fair value price target steady at NOK 0.4, signalling that the central valuation anchor in the model is unchanged. Analysts link this to only modest tweaks around long term earnings assumptions and execution risks, rather than any shift in the headline target itself. As you read on, you will see how this stable NOK 0.4 view fits with recent news, the bullish and bearish arguments, and what to watch to stay on top of the evolving Lifecare story.
Stay updated as the Fair Value for Lifecare shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Lifecare.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Several brokers covering Lifecare, including Deutsche Bank, Baird, Barclays and Citizens, have issued research that features higher price targets for the stock. They link these targets to their own views on the company's long term earnings potential.
-
Deutsche Bank's decision to set a new target of US$30 for Ethos, which trades under the LIFE ticker, signals that its analysts see valuation support at that level. This view is based on their assessment of the company's future cash generation and risk profile.
-
Baird, Barclays and Citizens have each outlined price target revisions for Ethos as well. Taken together, these changes point to a group of covering firms that are comfortable assigning higher fair value estimates than before, even while acknowledging the usual execution hurdles for a healthcare company.
🐻 Bearish Takeaways
-
Despite the higher targets from Deutsche Bank, Baird, Barclays and Citizens, the research still references execution risk. Your own view on Lifecare should factor this in when thinking about timelines, regulatory steps and the costs required to deliver on the underlying forecasts.
-
The range of revised targets, rather than a single figure, underlines that there is no consensus on upside for investors. This can leave Lifecare exposed to sentiment shifts if milestones take longer or differ from what these firms have built into their models.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 5 risks for Lifecare. See which could impact your investment.
How This Changes the Fair Value For Lifecare
-
Fair value for Lifecare is unchanged at NOK 0.4 in the latest update.
-
The long term revenue growth assumption is effectively unchanged, with only a very small model adjustment.
-
The long term profit margin assumption remains broadly stable at about 21.80%, with a minor technical adjustment.
-
The future P/E multiple is adjusted slightly from 136.36x to 136.16x.
-
The discount rate moves from 7.83% to 7.78% in the latest model.
Never Miss an Update: Follow The Narrative
Narratives connect Lifecare's business story to a set of financial assumptions and a fair value framework. They update as new data, clinical results and corporate decisions come through, so you can see how the story is changing over time.
Head over to the Simply Wall St Community and follow the Narrative on Lifecare to stay up to date on:
-
How the collaboration with TTP and work on implant design and automated production could influence manufacturing efficiency and unit costs.
-
What improved glucose sensor chemistry, potential CE marking for human use and possible activation of Sanofi commercial rights might mean for future market access.
-
Key execution risks around in vivo validation, production scale up, regulatory timelines and whether the Sanofi partnership progresses as expected.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LIFE.OL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
